(Q45158856)
Statements
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer (English)
scientific article published on 22 November 2004
No description defined